Hemogenyx Pharmaceuticals Plc (LON:HEMO)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 41.17M +532.3% |
| Revenue (ttm) | n/a |
| Net Income | -9.76M |
| EPS | -2.20 |
| Shares Out | 6.80M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,110 |
| Open | 623.00 |
| Previous Close | 620.00 |
| Day's Range | 592.27 - 639.00 |
| 52-Week Range | 134.23 - 1,800.00 |
| Beta | 1.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 25, 2026 |
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic pro... [Read more]
Financial Performance
Financial StatementsNews
Hemogenyx Pharmaceuticals PLC Announces Collaboration with Cellin Technologies
Hemogenyx Pharmaceuticals Signs Definitive Collaboration Agreement with Cellin Technologies for Manufacturing and Commercialization of HG-CT-1 CAR-T Therapy in Estonia Binding Agreement Converts LOI i...
Hemogenyx Pharmaceuticals PLC Announces Collaboration and Company Update
Collaboration with Vilnius University Hospital Santaros Klinikos on HG-CT-1 Clinical Application and Research LONDON, UK / ACCESS Newswire / July 29, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is...
Hemogenyx Pharmaceuticals PLC Announces Notice of AGM
Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Posting of Annual Report & Notice of Annual General Meeting LONDON, UK / ACCESS Newswire / June 5, 2026 / Hemogenyx Pharmac...
Hemogenyx Pharmaceuticals PLC Announces Grant of Options and Extension of Warrant Term
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Final Results
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DO...
Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Annual IND Report with FDA
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Tech Transfer Completion and Clinical Trial Update
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights
LONDON, UK / ACCESS Newswire / February 27, 2026 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the ...
Hemogenyx Pharmaceuticals PLC Announces Exercise of Warrants and Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
CORRECTION FROM SOURCE: Hemogenyx Pharmaceuticals PLC Announces Issue of Equity
The following amendment has been made to the Issue of Equity' announcement released on 10 February 2026. The sentence "through a direct subscription for 313,333 new ordinary shares in the Company at a...
Hemogenyx Pharmaceuticals PLC Announces Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Update on Admission of Shares
LONDON, UK / ACCESS Newswire / December 22, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, provides an update ...
Hemogenyx Pharmaceuticals PLC - Issue of Equity
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Publication of Prospectus
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICT...
Hemogenyx Pharmaceuticals PLC Announces Clinical Trial Update and Grant of Share Awards
DSMB Clearance to Proceed to the Next Dose Level of HG-CT-1 in Adult Patients, Opening Pediatric Recruitment, and Grant of Restricted Share Units to Hemogenyx Team LONDON, UK / ACCESS Newswire / Octob...
Hemogenyx Pharmaceuticals PLC Announces Clearance to Initiate Pediatric Enrolment
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018...
Hemogenyx Pharmaceuticals PLC Announces Half-year Report
Interim Results for the period ended 30 June 2025 LONDON, UK / ACCESS Newswire / September 30, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designe...
Hemogenyx Pharmaceuticals PLC Signs Letter of Intent
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia First Potential Near-Term Revenue Opportunity LONDON / ACCESS...
Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety
Third Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation LONDON, UNITED KINGDOM / ACCESS Newswire / September 17, 2025 / Hemogenyx Pharmaceuticals plc is pleased ...
Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), is pleased to announce that the Company ha...
Made Scientific and Hemogenyx Pharmaceuticals Announce Technology Transfer and Manufacturing Partnership to Advance HG-CT-1, an Autologous CAR-T Cell Therapy for Acute Myeloid Leukemia
PRINCETON, N.J. and NEW YORK , Sept.
Hemogenyx Pharmaceuticals PLC Announces Manufacturing Partnership with Made Scientific
Hemogenyx Pharmaceuticals Announces Manufacturing Partnership with Made Scientific to Advance HG-CT-1 CAR-T Therapy CITY OF LONDON, GB / ACCESS Newswire / September 8, 2025 / Hemogenyx Pharmaceuticals...
Hemogenyx Pharmaceuticals PLC Announces Issue of Convertible Loan Notes
LONDON, GB / ACCESS Newswire / September 1, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £620,000 through the issue of convertible loan notes (the "CLNs")....
Hemogenyx Pharmaceuticals PLC Announces Result of Audit Tender
LONDON, UK / ACCESS Newswire / August 29, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory ...